SHR-1802

BIOLOGICAL2 trials

Sponsors

Jiangsu HengRui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.

Conditions

Advanced Solid TumorMalignant Tumours

Phase 1

A Trial of SHR-1802 in Patients With Failure of Standard Treatment for Advanced Malignant Tumours

CompletedNCT04414150

Jiangsu HengRui Medicine Co., Ltd.Malignant Tumours

Start: 2020-06-17End: 2022-03-15Updated: 2022-10-26

A Study of SHR-1802 in Combination With Adebrelimab in Patients With Advanced Solid Tumors

Shanghai Hengrui Pharmaceutical Co., Ltd.Advanced Solid Tumor

Start: 2023-04-28End: 2025-12-31Target: 132Updated: 2023-06-02

Related Papers

Safety, tolerability, and pharmacokinetics of an anti-LAG-3 antibody SHR-1802 in patients with advanced solid tumors: a phase I dose-escalation and dose-expansion study

Therapeutic Advances in Medical Oncology2023-01-0119 citations